Nonoccupational HIV postexposure prophylaxis: A new role for the emergency department

Annals of Emergency Medicine

Volumn 36, Issue 4, 2000, Pages 366-375

  Clayton Merchant, Roland ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; STAVUDINE; ZIDOVUDINE;

CLINICAL PROTOCOL; EMERGENCY WARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MONKEY DISEASE; NONHUMAN; OCCUPATIONAL EXPOSURE; PERINATAL INFECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SEXUAL INTERCOURSE; SIDE EFFECT; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0033773997     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1067/mem.2000.109511     Document Type: Article

References (77)

1. Centers for Disease Control and Prevention
2. Gay men report high rates of unprotected anal sex with partners of unknown or discordant HIV status
3. Increase in unprotected anal intercourse with casual partners among Sydney gay men in 1996-98
4. Post-exposure prophylaxis for HIV infection in gay and bisexual men: Implications for the future of HIV prevention
5. Sexual exposure to HIV infection: Is there a role for emergency prophylaxis?
6. Should preventive HIV therapy be expanded? Officials ponder using drugs after accidental sexual exposure to AIDS virus
7. Morning-after HIV experiment starts in S.F./ Project to offer drugs, counseling
8. Morning after: HIV experts worry it will erase preventive gains
9. Emergency treatment to stop AIDS virus
10. Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy
11. Post-exposure prophylaxis against HIV infection in health care workers
12. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use
13. Case-control study of HIV seroconversion in HCWs after percutaneous exposure to HIV infected blood - France, United Kingdom, and United States, January 1988-August 1994
14. A case-control study of HIV seroconversion in health care workers after percutaneous exposure
15. Human immunodeficiency virus postexposure management of healthcare workers: Report of a workshop
16. Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV
17. Public Health Service guidelines for the management of health care workers: Exposures to HIV and recommendations for postexposure prophylaxis
18. Rape and subsequent seroconversion to HIV
19. Anti-HIV substances for rape victims
20. Rape and subsequent seroconversion to HIV
21. HIV testing, counseling, and prophylaxis after sexual assault
22. Guidelines for treatment of sexually transmitted diseases
23. Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault
24. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use
25. The care of persons with recent sexual exposure to HIV
26. Animal studies of prophylaxis
27. Effects of initiation of 3'-azido,3'-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus
28. Nonhuman primate models for evaluation of AIDS therapy
29. Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus
30. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine
31. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus (SIV) depends critically on timing of initiation and duration of treatment
32. Prevention of simian immunodeficiency virus, (SIV) or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005
33. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques
34. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells
35. Should preventive antiretroviral treatment be offered following sexual exposure to HIV? Not yet!
36. A double-blind, placebo-controlled study of the safety and efficacy of Retrovir (zidovudine) as a chemoprophylactic agent in health care workers exposed to HIV
37. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
38. Efficacy of zidovudine in preventing HIV transmission from mother to infant
39. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand, 1996-1998
40. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial
41. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
42. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial
43. The role of skin dendritic cells in the initiation of human immunodeficiency virus infection
44. Past-exposure prophylaxis after sexual or drug use exposure to HIV: Final results from the San Francisco post-exposure prevention (PEP) project
45. Evaluating seroconversion in the San Francisco post-exposure prevention project (PEP)
46. Non-occupational post-exposure prophylaxis at a Boston community health center
47. Candidate antiretroviral agents for use in postexposure prophylaxis
48. Immune response to human immunodeficiency virus (HIV) in health care workers occupationally exposed to HIV-contaminated blood
49. Postexposure prophylaxis after nonoccupational HIV exposure: Clinical, ethical and policy considerations
50. Probability of heterosexual transmission of HIV: Relationship to the number of unprotected sexual contacts
51. Probability of female-to-male transmission of HIV-1 in Thailand
52. HIV infectivity by contraceptive method from a partner study in northern Thailand
53. Model-based optimization of infectivity parameters: A study of the early epidemic in San Francisco
54. Modeling HIV infectivity: Must sex acts be counted?
55. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures: A prospective evaluation
56. A model-based estimate of HIV infectivity via needle sharing
57. Zidovudine for the prevention of HIV transmission from mother to infant
58. Mode of delivery and gestational age influence perinatal HIV-1 transmission
59. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations
60. Sexual transmission of HIV
61. Infectiousness of HIV between male homosexual partners
62. Prophylaxis for occupational exposure to HIV
63. Combination chemotherapy for human immunodeficiency virus-1
64. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase
65. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection
66. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
67. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of >500/mm3: AIDS Clinical Trials Group Protocol 208
68. Viral dynamics in human immonodeficiency virus type 1 infection
69. New national nonoccupational HIV postexposure prophylaxis registry established
70. A review of protease inhibitors (PI) use in 89 pregnancies
71. US Public Health Service task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States
72. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection